Clinical Trial Update: A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating immune response in pediatric kidney transplant recipients treated with daclizumab (Zenapax); results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Daclizumab (Zenapax) (daclizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Kidney Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2016-01-13